Allergan Buys MAP Pharmaceuticals
said this morning that Allergan has agreed to acquire MAP Pharmaceuticals, in a deal worth approximately $958M. Allergan said it will pay $25.00 per share for publicly held MAP Pharmaceuticals. MAP Pharmaceuticals develops biopharmaceuticals, with its lead product being LEVADEX, an orally inhaled drug under trials for treating migraines in adults.
posted on Wednesday, January 23, 2013
> Allergan Buys Dermatology Product
> Inamed Receives Bid From Allergan
> Allergan To Cut 1500 Jobs
> Allergan Adopts Poison Pill
> Allergan: Valeant Offer Grossly Inadequate